SCLEROTINIA SCLEROTIORUM (LIB.) DE BARY: INSIGHTS INTO THE PATHOGENOMIC FEATURES OF A GLOBAL PATHOGEN



Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

Background Most patients with advanced melanomas relapse after checkpoint blockade therapy.Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting.Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum.To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MA

read more